BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...
Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback